Article

Efficacy, safety, and predictability encouraging for wavefront-guided epi-LASIK

As follow-up increases, results continue to be favorable in the prospective multicenter study evaluating wavefront-guided epi-LASIK treatment for myopia using the Norwood EyeCare Epikeratome, reported Marguerite B. McDonald, MD.

As follow-up increases, results continue to be favorable in the prospective multicenter study evaluating wavefront-guided epi-LASIK treatment for myopia using the Norwood EyeCare Epikeratome, reported Marguerite B. McDonald, MD.

The study enrolled 133 eyes of 70 patients with an average preoperative SE of -2.88 D (range -0.5 to -7.9 D), uncorrected visual acuity (UCVA) of 20/200, and best-corrected visual acuity (BCVA) of 20/20. All ablations are being performed with the STAR S4 excimer laser (VISX/AMO).

With 71 eyes seen at 3 months, mean SE is plano and the achieved refraction is within 0.25 D of plano in 90% of eyes. Visual outcomes are impressive as well. While mean UCVA was only 20/50 on days 1 and 4 postoperative and improved to 20/40 on day 7, at 3 months after the surgery, 87% of eyes had achieved UCVA of 20/20 or better, 63% were able to see 20/16 or better uncorrected, and UCVA was 20/12.5 or better in 23%. No eyes have lost any lines of BCVA, and while none could see 20/12.5 or better with best correction preoperatively, that level of vision was achieved by 33% of eyes tested at 3 months.

Pain ratings during the first few days after the procedure averaged slightly over 3 on a scale of 0 to 10, but dropped to 1.7 by day 7. Haze was minimal during early follow-up and was absent in all eyes at month 3.

"We are most encouraged by these early results for wavefront-guided epi-LASIK and look forward to longer follow-up," said Dr. McDonald, clinical professor of ophthalmology, Tulane University, New Orleans.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
© 2025 MJH Life Sciences

All rights reserved.